Polyunsaturated Fatty Acids-based Bars Effect on Metabolic Syndrome Patients

May 30, 2026 updated by: Maria Aslam, University of Lahore

Effects of Polyunsaturated Fatty Acids-based Bars on Lipid Profile Among Patients With Metabolic Syndrome

This study aimed to manage dyslipidemia through Polyunsaturated fatty acids based bar among patients with metabolic syndrome.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study was conducted at Chaudhry Muhammad Akram Teaching & Research Hospital, Lahore. Total 60 individuals diagnosed with metabolic syndrome, like deranged lipid profile, high blood pressure (ranges mild to moderate), and elevated levels of HbA1c (5.6%-6.4%), aged between 40 to 65 years were part of the study. The participants were randomly selected and divided into two groups.

Control group (T 0 ) was given one jelly candy as mid-morning snack. The experimental group (T 1 ) was given PUFA bar one each daily The follow-up for patients has been conducted monthly, all laboratory test (blood pressure, lipid profile, HbA1c and CRP) has been done on 1st and after 8 weeks. The baseline and post-test study data is compared to test the study hypothesis.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • University of Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Metabolic syndrome patient's age 40 to 65 years with BMI (above 25 kg/m 2 ) was major part of this study.
  • Patients having Triglyceride levels range from mild to moderate (150 to 499 mg/dL) are included in the study.
  • Patients having LDL (Low density lipoprotein) range from mild (130-159 mg/dL) to moderate (160-189 mg/dL) are included in the study.
  • Patients having HDL (High-density lipoprotein) range from mild to moderate (60 mg/dL or higher) have been included in the study.

Exclusion Criteria:

  • Lactating and pregnant women will not be included.
  • Patients who are using any kind of medicine.
  • Any person allergic to nuts.
  • Adults suffering from critical health conditions, including cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group T0
participants have taken one jelly candy as a mid-morning snack for a duration of 2 months.
Dietary supplement: Jelly Candy
participants were advised to take one jelly candy as a mid-morning snack for a duration of 2 months.
Experimental: Experimental group T1
participants have taken one PUFA bar as a mid- morning snack for a duration of 2 months.
Dietary supplement: PUFA Bar
Participants were advised to taken one PUFA bar as a mid- morning snack for a duration of 2 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Mass Index
Time Frame: 60 days
BMI is defined as body weight in kilograms divided by height in meters squared (kg/m²). BMI cut-off points are used to assess weight status, categorizing individuals as underweight, normal, overweight or obese. Obesity is further classified into grades 1, 2 and 3.
60 days
Lipid Profile
Time Frame: 60 days
Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides levels were measured.
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 6, 2025

Primary Completion (Actual)

May 15, 2025

Study Completion (Actual)

July 16, 2025

Study Registration Dates

First Submitted

May 30, 2026

First Submitted That Met QC Criteria

May 30, 2026

First Posted (Actual)

June 4, 2026

Study Record Updates

Last Update Posted (Actual)

June 4, 2026

Last Update Submitted That Met QC Criteria

May 30, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-UOL-FAHS/570/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslipidemia

Clinical Trials on Jelly Candy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe